Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Exploring New and Novel Treatments in Neurofibromatosis
Release Date: February 20, 2020
Expiration Date: February 20, 2021
Media: Internet - based
This continuing medical education (CME) activity is designed to inform healthcare providers on the latest information on new and novel treatment options for the management of neurofibromatosis.
Acknowledgment of Support
This activity is funded by PER®.
Instructions for This Activity and Receiving Credit
Upon successful completion of this educational activity, you should be better prepared to:
- Describe the pathophysiologic rationale for the use of targeted therapies in patients with neurofibromatosis
- Evaluate recent clinical trial findings regarding the efficacy and safety of targeted therapies for neurofibromatosis
- Discuss the potential benefits and risks associated with the treatment of neurofibromatosis
Associate Professor of Medicine
Division of Oncology, Department of Medicine
Washington University School of Medicine
St. Louis, MO
This activity was written by PER® editorial staff under faculty guidance and review.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Disclosures: Jian L. Campian. MD, PhD, has no relevant financial relationships with commercial interests.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.